Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
XERSthis companyXeris Biopharma Holdings, Inc.	$15.43	2,242.86×	92×	4.32×	93.32×	-804.3%	81.7%	8.5%	0.2%	4.0%	8.9%	2.2%	2.76×	-5.77×	0.86×	2.19×	0.0%	5	1.35	2	C
CORTCorcept Therapeutics Incorporated	$75.72	36.63×	5.58×	4.75×	51.2×	-30.4%	98.3%	5.9%	13.1%	15.4%	6.7%	3.9%	0.01×	-1.67×	0×	2.92×	0.0%	6	30.98	3	B
ETONEton Pharmaceuticals, Inc.	$59.59	-99.47×	17.4×	5.69×	107.83×	-174.2%	53.5%	0.1%	-5.8%	-17.6%	0.1%	2.2%	1.19×	1.19×	0.02×	1.57×	0.0%	7	12.98	3	B
MBXMBX Biosciences, Inc. Common Stock	$53.44	-13.25×	3.12×	0×	-12.42×	-96.3%	0.0%	0.0%	0.0%	-23.6%	-26.5%	-7.1%	0×	0.86×	0×	24.62×	0.0%	1	58.99	2	C
MNKDMannKind Corporation	$4.18	283.5×	-33.97×	4.97×	77.45×	-1108.3%	82.5%	11.1%	1.7%	-11.5%	5.8%	0.8%	-9.28×	14.48×	2.81×	1.7×	0.0%	1	-4.55	2	C+
SEPNSepterna Inc	$49.27	-25.35×	3.23×	26.85×	-24.05×	-147.7%	100.0%	-175.8%	-106.4%	-12.8%	-15.8%	8.9%	0.06×	2.05×	0×	4.73×	0.0%	3	6.86	2	C
Peer median	—	-13.25×	3.23×	4.97×	51.2×	-147.7%	82.5%	0.1%	0.0%	-12.8%	0.1%	2.2%	0.01×	1.19×	0×	2.92×	0.0%	3	12.98	2	—